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Abstract  
 
Gene therapy approaches delivering neurotrophic factors have offered promising results in both 
pre-clinical and clinical trials of Parkinson’s disease (PD). However, failure of glial cell line-derived 
neurotrophic factor in phase II clinical trials has sparked a search for other trophic factors which may 
retain efficacy in the clinic. Direct protein injections of one such factor, insulin-like growth factor 1 
(IGF-1), in a rodent model of PD has demonstrated impressive protection of dopaminergic neurons 
against 6-hydroxydopamine (6-OHDA) toxicity. However, protein infusion is associated with surgical 
risks, pump failure and significant costs. We therefore used lentiviral vectors to deliver Igf-1, with a 
particular focus on the novel integration-deficient lentiviral vectors (IDLVs). A neuron-specific 
promoter, from the human synapsin 1 gene, excellent for gene expression from IDLVs, was 
additionally used to enhance Igf-1 expression. An investigation of neurotrophic effects on primary rat 
neuronal cultures demonstrated that neurons transduced with IDLV-Igf-1 vectors had complete 
protection upon withdrawal of exogenous trophic support. Striatal transduction of such vectors into 
6-OHDA-lesioned rats, however, provided neither protection of dopaminergic substantia nigra 
neurons nor improvement of animal behavior.  
 
Key words: IGF-1, Parkinson’s disease, lentiviral vectors, IDLVs 
3 
 
Introduction  
 
Parkinson’s disease (PD) results from a gradual loss of neurons within the dopaminergic substantia 
nigra pars compacta (SNpc) and their projections to the striatum1. Therapeutic strategies using 
trophic factors have offered encouraging results in both pre-clinical and open-label clinical trials of 
PD2-6. However, administration of the most promising factor, glial cell line-derived neurotrophic factor 
(GDNF), was unsuccessful in double blind, phase II clinical trials7. Hence, the search for other 
neurotrophic factors has been stepped up4-6, 8. One such factor is insulin-like growth factor 1 (IGF-1).  
 
IGF-1 is well known as a peripheral growth factor (secreted mainly by hepatocytes) that regulates 
cell metabolism and tissue remodeling9. In recent years, a role of IGF-1 within the central nervous 
system (CNS) has been identified, appearing to be both neuroprotective and neurotrophic, and 
important in the maintenance of adult CNS homeostasis10, 11. IGF-1 is also considered a pro-survival 
factor, upregulated in all types of brain injuries12. IGF-1 exerts its multiple effects through binding to 
IGF-1 receptors, phosphorylation of which activates multiple downstream signaling pathways, 
resulting in inhibition of apoptosis and regulation of both cell differentiation and cell proliferation13-15. 
 
The exact role of IGF-1 in PD remains unclear, with studies reporting a decrease in plasma levels 
associated with cognitive decline16. Conversely, in post-mortem PD samples, an increase in plasma 
IGF-1 levels was observed17, suggesting that there may be a compensatory increase in IGF-1 levels 
due to the ongoing cell loss. Guan et al.18 and Offen et al.19 demonstrated IGF-1 neuroprotection 
against 6-hydroxydopamine (6-OHDA) toxicity in human neuroblastoma and rodent neuronal cell 
cultures. Other studies using intracerebral injections of IGF-1 protein, after 6-OHDA lesioning of the 
nigrostriatal pathway, have suggested that IGF-1 administration can prevent dopaminergic cell loss 
and behavioral deficits in this pre-clinical animal model of PD18, 20, 21. However, direct protein infusion 
via a surgically implanted pump has a number of disadvantages, including limited distribution, 
device-related side effects and activation of the immune response7, 22. An alternative approach, 
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which may overcome these disadvantages, is the use of gene therapy to deliver the gene for IGF-1 
through a viral vector system. 
 
Numerous reports have shown both efficient and stable expression of GDNF from lentiviral vectors 
(LVs) in pre-clinical animal models of PD23-27. We have previously demonstrated that the novel 
integration-deficient LVs (IDLVs) are as efficient as their standard integration-proficient counterparts 
(IPLVs) at transducing rodent eye and brain cells in vivo28 but have enhanced biosafety due to their 
reduced risk of insertional mutagenesis28, 29. Our recent data have confirmed efficient and long-
lasting in vivo transduction with IDLV-hGDNF, mediating therapeutic effects in a PD rat model30.  
 
In the present study, the potential neuroprotective effects of IGF-1 were investigated through IDLV-
mediated expression, with IPLV-Igf-1 vectors used as controls. To maximize the levels of transgene 
expression, which can be addressed by the choice of promoters specific to target cells31-33, we 
initially examined transduction efficiency and cell-type specificity of LVs through expression of the 
gene encoding enhanced green fluorescent protein (eGFP). We compared vectors driven by the 
cytomegalovirus promoter (CMVp), human glial fibrillary acidic protein promoter (GFAPp) and 
human synapsin 1 promoter (SYNp). In particular, LV-mediated in vivo eGFP expression from IDLV-
SYNp vectors displayed efficient, long-term, and comparable transduction efficacy with their 
integrating counterparts. Following vector transduction in rat primary ventral mesencephalic cell 
cultures and 6-OHDA-lesioned rats, the neuronal specificity of LV-SYNp vectors, beneficial to 
enhance Igf-1 expression34, was ascertained. Further investigation of LV-mediated IGF-1 
neuroprotection demonstrated enhanced in vitro survival of rat cortical neurons against withdrawal 
of exogenous trophic factors. Igf-1 expression from LVs was subsequently confirmed in 6-OHDA rat 
model of PD although neither dopaminergic cell survival nor animal behavioral recovery was 
improved following vector transduction. 
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Materials and Methods 
 
Lentiviral vector production and titration: Concentrated stocks of the 3rd generation lentiviral 
vectors, both IPLVs and IDLVs, were produced by calcium phosphate transfection in HEK-293T cells 
as previously described28. Lentiviral transfer plasmids used in this study were pRRLsc-CMVp-eGFP-W, 
pRRLsc-hGFAPp-eGFP-W, pRRLsc-hSYNp-eGFP-W, pRRLsc-CMVp-Gdnf-IRES-eGFP-W, pRRLsc-SFFVp-
eGFP-CMVp-Igf-1-W, and pRRLsc-SFFVp-eGFP-hSYNp-Igf-1-W; Gdnf and Igf-1 cDNAs were from rat. 
All vectors were self-inactivating, contained a central polypurine tract/central termination sequence 
(cPPT/cTS) and Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE, 
abbreviated as W on plasmid names), and were pseudotyped with the vesicular stomatitis virus G 
protein (VSV-G) envelope. Viral titres were quantified by either flow cytometry using a FACSCanto II 
(BD Biosciences, UK), qPCR using Rotogen (QIAgen, UK) as described 28, or by p24 ELISA kit (SAIC, 
Frederick, Maryland, USA) following the manufacturer’s instructions. 
 
Animals: Animal procedures were performed in accordance with the UK Animals (Scientific 
Procedures) Act, 1986. Sprague-Dawley rats (Charles River, UK) were maintained in a standard 12-
hour light/dark cycle with free access to food and water. For primary cell cultures, E14-E15 embryos 
were used for ventral mesencephalic (VM) cultures whilst E17-E18 embryos were harvested for 
cortical neuronal cultures. For in vivo work, 35 male rats weighing 250-300 g at the beginning of the 
study were housed 2-3 rats/cage and were split randomly into experimental groups, either for 5-
month eGFP experiment or 6-week IGF-1 experiment. 
 
Preparation of primary cultures of embryonic brain cells: Rat embryos were rapidly removed and 
kept in ice-cold dissection buffer containing 1X Hank’s balanced salt solution (Invitrogen, UK), 100 
units/ml penicillin (PAA, UK), 100 μg/ml streptomycin (PAA, UK), and 100 μM ascorbic acid (Sigma 
Aldrich, UK). The ventral mesencephalons containing the subtantia nigra or cortices were dissected 
under a Wild M3Z dissecting microscope (Wild Heerbrugg, Switzerland) with illumination support by a 
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KL2500 LCD instrument (Schott UK Ltd., UK). Brain tissues were dissociated in 0.05% trypsin/EDTA (PAA, 
UK) supplemented with 0.02% DNaseI (Promega, UK) for 5-20 min at 37oC. Tissues were washed twice 
in culture medium prior to de-aggregation by repeated pipetting (p1000, p200, p20, and p10 
pipettors). VM or cortical neuronal culture medium included neurobasal medium (Invitrogen, UK), 2% 
B27 (Invitrogen, UK), 0.25% GlutaMax (Invitrogen, UK), 1% FBS (PAA, UK), and 100 μM ascorbic acid 
(Sigma Aldrich, UK); 10 ng/ml TGF-βIII was additionally added into VM neuronal cultures. VM 
astroglial culture medium included DMEM (PAA, UK), 1% N2 (Invitrogen, UK) and 10% FBS. The cell 
suspension was then passed through a 40-100 μm cell strainer and subsequently centrifuged at 80-
200 g for 5 min. The cell pellet was resuspended in pre-warmed culture medium. Live cells were 
counted by 0.2% tryphan blue staining (Sigma Aldrich, UK). For VM neuronal cultures, 100 µl cell 
suspension containing 105 live cells was plated onto a 13 mm coverslip (Thermo Scientific, UK), which 
was pre-coated overnight with 50 μg/ml poly-D-lysine and placed inside a well of a 24-well plate. 
After 30 minutes for cell adhesion, each well was carefully topped up with 500 μl culture medium. For 
VM astroglial cultures, 500 µl cell suspension containing 5 x 104 live cells/well was plated in uncoated 
24-well plates and cultured at 37oC for 48 hours. The supernatant, containing clumps of unattached 
cells (most of those were dead neurons), was aspirated and replaced with fresh medium. For 
cortical neuronal cultures, a density of 3 x 106 live cells/well was plated in 24-well plates pre-coated 
with 50 μg/ml poly-D-lysine. Cell cultures were maintained by changing the medium every 1-3 days. 
The methods described in this section were amended from published methodologies of Pruszak et al. 
for VM neuronal cultures35; Takeshima et al. for VM astroglial cultures36; and Boulos et al. for cortical 
neuronal cultures37. 
 
LV transduction in vitro: Cell culture medium was changed 2 hours prior to vector transduction. 
Concentrated vector stocks were diluted in medium for an optimized MOI 10 (eGFP transducing 
units/ml) or MOI 30 (qPCR vector units/ml) and added gently to the wells; mock cells received no 
vector.  
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Trophic support withdrawal strategy: Cortical neuronal cultures had the medium changed at day 1 
in vitro, 2 hours prior to transduction with IDLVs at MOI 30 (qPCR vector units/ml), including: CMVp-
eGFP, CMVp-Gdnf-IRES-eGFP, SFFVp-eGFP-CMVp-Igf-1, and SFFVp-eGFP-SYNp-Igf-1 vectors. Cells 
were maintained for 3 days before withdrawal of exogenous trophic factors. For this, the medium 
was aspirated; normal culture medium was added into trophic factor-supported groups whereas 
only neurobasal medium was added to trophic factor-free groups. Cell viability was assessed by MTT 
assay after an additional 3 days. 
 
MTT assay: Cell viability was evaluated by using a colorimetric assay employing MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma Aldrich, UK). A final concentration of 0.5 
mg/ml MTT was added to cell cultures and subsequently incubated at 37ºC for 3 hours. Formazan 
crystals produced in this reaction were solubilized in dimethyl sulfoxide (VWR, UK). The optical cell 
density in each well was then measured by spectrometric analysis at OD570, using Gen5 data analysis 
software (BioTek, UK).  
 
Immunocytochemistry: For characterization of VM cell cultures, cells were gently washed in ice-cold 
1X PBS and then fixed in 4% PFA for 10-15 min. Fixed cells were washed twice in 1X PBS, 
permeabilized in 1X PBS-T (1X PBS containing 0.25% Triton-X 100) for 10 min, and incubated in 1% BSA 
blocking buffer (in 1X PBS-T) for 30 min. Primary antibodies were separately added and incubated at 
4oC overnight. The antibody was either mouse anti-NeuN (1:500, Millipore, UK) or rabbit anti-Tuj1 
(1:3000, Sigma, UK) for neurons; rabbit anti-GFAP (1:500, DAKO, UK) for astrocytes; rabbit anti-Iba1 
(1:500, WAKO, UK) for microglia; rabbit anti-TH (1:1000, Millipore, UK) for dopaminergic neurons; 
rabbit anti-VGLUT1 (1:500, Synaptic systems, Germany) for glutamatergic neurons; or rabbit anti-
GAD67 (1:50, Synaptic systems, Germany) for GABAergic neurons. After 3 washes in 1X PBS, cells 
were incubated with the corresponding secondary antibodies diluted in 1% BSA blocking buffer at 
room temperature, for an hour, in the dark. The antibody (1:500, Invitrogen, UK) was either goat anti-
rabbit AlexaFluor555 or goat anti-mouse AlexaFluor555. After another 3 washes in 1X PBS, cells were 
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incubated with 1 µg/ml 4,6-diamidino-2-phenylindole (DAPI) for 15 min, in the dark. Three washes in 
1X PBS were then performed. Images of cells were subsequently captured and counted. Cells 
incubated with only primary or secondary antibody were used as negative controls for the staining. 
For estimation of the percentage of eGFP-producing cells in primary cell cultures transduced with 
LV-eGFP vectors, cells were washed in ice-cold 1X PBS and fixed in 4% PFA for 10-15 min. After 3 
washes in 1X PBS, cells were incubated with 1 µg/ml DAPI for 15 min to stain nuclei. Another 3 washes 
in 1X PBS were performed prior to cell capture.  
 
Intrastriatal injection of LVs: Animals were kept under isoflurane-induced anesthesia (5% in 100% O2 
for induction and 2.5% in 100% O2 for maintenance). The nose bar was set at -3.3 mm. All injections 
were made using a 25 µl Hamilton syringe held within an automated UltraMiniPump III (World 
Precision Instruments); injection rate was 0.5 µl/min. Two burr-holes were made into the skull above 
the right striatum with an Ideal Micro-drill (Harvard Apparatus, UK). Equivalent vector titres (5 µl/hole, 
109 qPCR vector copies/ml or 2x104 ng p24/ml) were injected following stereotactic coordinates: (1) 
AP = +1.8 mm, ML = -2.5 mm relative to bregma and DV = -5.0 mm relative to dura; (2) AP = 0.0 mm, 
ML = -3.5 mm relative to bregma and DV = -5.0 mm relative to dura. The needle was left in place for 
3 min before being retracted. In the eGFP experiment, animal groups included IPLV-SYNp-eGFP (n 
=5) and IDLV-SYNp-eGFP (n = 5). In the IGF-1 experiment, animal groups (n = 5 per group) were: (1) 
mock (0.9% sterile saline); (2) IPLV-CMVp-Igf-1; (3) IDLV-CMVp-Igf-1; (4) IPLV-SYNp-Igf-1; and (5) IDLV-
SYNp-Igf-1. 
 
6-OHDA lesioning: Two weeks post-vector transduction, animals were injected with a combined 
solution of pargyline (5 mg/kg, i.p) and desipramine (25 mg/kg, i.p). Thirty minutes later, 6-OHDA 
dissolved in a solution containing 0.9% saline and 0.02% ascorbic acid was injected into the same 
positions of vector administration (2 µl/site, 2.5 µg/ µl). All reagents were purchased from Sigma 
Aldrich, UK. 
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Drug-induced rotational asymmetry tests: In the IGF-1 experiment, animal behavior was tested 
weekly, from one week after 6-OHDA lesioning for a period of 4 weeks. Amphetamine-induced 
rotational tests were carried out first, followed by apomorphine tests 3 days later. In each test, 
animals were acclimatized in 40 cm-diameter bowls for 30 min prior to injection with amphetamine 
(5 mg/kg, i.p; Sigma Aldrich, UK) or apomorphine (1 mg/kg, i.p; Tocris, UK). Net rotational asymmetry 
was assessed for 90 min post-injection as one whole head to tail revolution, with contralateral and 
ipsilateral turns being scored separately.  
 
IGF-1/GDNF detection by ELISA: In the in vitro experiment, cortical neuronal cultures were collected 
at days 3 and 6 post-transduction with IDLV-Igf-1 or -Gdnf vectors. In the in vivo experiment, rats 
receiving IPLV- or IDLV-Igf-1 vectors, or mock-treated animals were sacrificed with CO2 followed by 
cervical dislocation. The striata were dissected and snap-frozen in liquid nitrogen. Tissue was 
homogenized in complete lysis buffer (Roche, UK) and centrifuged at 14000 g, 4oC for 15 min. Levels 
of IGF-1 or GDNF that were produced in either cell cultures or rat striata were determined with a rat 
IGF-1 ELISA kit (R&D System, UK) or a human GDNF ELISA kit (Promega, UK) following the 
manufacturers’ instructions.  
 
Immunohistochemistry: Rats were sacrificed as described above. Whole brains were fixed in 4% PFA 
for 3 days at 4oC. Coronal striata containing sections from the eGFP experiment or nigra containing 
sections from the IGF-1 experiment were sliced on a vibrating microtome (Campden Instruments, UK) 
at 50 µm thickness and kept in ice-cold 1X PBS. Sections were subsequently incubated in 1% BSA 
blocking buffer (Sigma Aldrich, UK) for an hour. Striata containing sections were incubated with 
primary antibody, either mouse anti-NeuN (1:500, Millipore, UK), rabbit anti-GFAP (1:500, DAKO, UK) 
or rabbit anti-Iba1 (1:500, WAKO, UK) whilst SN containing sections were incubated with rabbit anti-
TH (1:1000, Millipore, UK) overnight at 4oC, followed by three washes in 1X PBS. Sections were then 
incubated with goat anti-mouse or goat anti-rabbit AlexaFluor555 antibody (1:500, Invitrogen, UK) as 
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appropriate for 1 hour, in the dark. After three washes in 1X PBS, sections were incubated with 1 
µg/ml DAPI (Sigma Aldrich, UK) for 15 min and mounted onto SuperFrost slides.  
 
Image capture: Both cultured cells and brain sections were visualized under an inverted 
fluorescence Axio Observer D1 microscope. Images were taken with an AxioCam combined with 
AxioVision software. Equipment and software were purchased from Carl Zeiss, UK. 
 
Cell counting: Since cultured cells dispersed unevenly, 9 fields/well were selected manually at the 
same positions in all wells to avoid bias and for more accurate statistical analysis. An image was 
captured from each field and the cell numbers were counted manually using ImageJ software 
(National Institutes of Health, Maryland, US). DAPI+ cell nuclei were scored to obtain the total cell 
number. The DAPI channel was subsequently merged with another fluorescence channel to score 
the total number of a specific cell type. Averages of cell numbers from the 9 fields were then used to 
obtain the total and marker-positive cell numbers within each well. For brain sections containing the 
SN, overlapping images from each section were captured and stitched automatically with 
AxioVision software to create a mosaic image of the section. According to the Rat Brain Atlas 
(Paxinos and Watson, 2007), two hemispheres of the SNpc were identified on each section. Only TH+ 
cells within these regions were counted (using ImageJ software), separately between the left and 
right hemispheres. Cell counts from approximately thirty SNpc-containing serial sections were 
subsequently averaged to obtain the total TH+ cell number per section of the SNpc in the 
corresponding brain hemisphere.  
 
Measurement of eGFP intensity: For cultured cells, 9 fields/well of 24-well plates were selected and 
each field was individually captured as described above. The intensity of eGFP in each field was 
scored by AxioVision software. An average of intensity from the 9 fields was then taken and 
expressed as arbitrary units (a.u.)/µm2. For brain sections containing the striatum, following image 
capture the area of the striatum on each section was identified according to the Rat Brain Atlas 
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(Paxinos and Watson, 2007). The intensity of eGFP within this area was quantified with AxioVision 
software and expressed as a.u./µm2. The values from approximately 60 striatal sections from each 
brain were then averaged to obtain the value for the corresponding brain. 
 
Statistical analysis: Using Prism 5 software (GraphPad, San Diego, California, USA), data were 
analyzed and shown as the means ± S.E.M, with error bars representing the S.E.M. In vitro experiments 
were done in triplicate. Comparisons of statistical significance were assessed by one- or two-way 
ANOVA followed by post-hoc tests. Significance levels were set at *p < 0.05, **p < 0.01, ***p < 0.001.  
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Results  
 
Lentiviral transduction efficiency and cell-type specificity in rat primary ventral mesencephalic (VM) 
cell cultures 
 
We initially investigated transduction efficiency and transcriptional targeting of LVs through eGFP 
expression in rat primary VM cell cultures. IPLV- and IDLV-eGFP vectors driven by CMVp, GFAPp, or 
SYNp promoters were used to transduce the VM neuronal or astroglial cultures at an optimized MOI 
10 (Figure S1). The number of eGFP-expressing cells and eGFP intensity were evaluated 3 days post-
vector transduction. The types of cells expressing eGFP were studied through fluorescence co-
localization with TH (for dopaminergic neurons), NeuN/Tuj1 cells (for total neurons) or GFAP (for total 
astrocytes). 
 
In cultures containing 60% neurons (including 4% TH+ neurons) and 13% astrocytes (as characterized 
in Figure S2a), we identified a highly significant reduction in the percentage of cells expressing eGFP 
from LV-GFAPp compared to LV-CMVp and LV-SYNp vectors, regardless of vector integration 
proficiency (Figure 1a); and up to two-fold difference in eGFP intensity between IPLVs and IDLVs 
(Figure 1b). Transduction efficiency of IPLV-SYNp and IPLV-CMVp vectors was comparable, but the 
percentage of eGFP-expressing cells following transduction with IDLV-SYNp vectors was almost 
double the percentage observed in cells transduced with IDLV-CMVp vectors. Representative 
images are shown in Figure 1c. We also quantitated the percentage of dopaminergic neurons (TH+) 
expressing eGFP. Despite no significant difference in the total TH+ cell number between groups (p = 
0.06, Figure 1d), 60% TH+ cells were transduced by either IPLV-CMVp or IPLV-SYNp vectors (Figure 1e). 
The expression of eGFP was moderate in TH+ cells transduced with IPLV-CMVp or IPLV-SYNp whilst no 
eGFP expression in TH+ cells was observed following IPLV-GFAPp vector transduction (Figure 1f).  
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In astroglial cultures containing 36% astrocytes and 1% neurons (as characterized in Figure S2b), the 
cell-type specificity of LV-SYNp vectors was significantly different of that observed with the other 
vectors in both the total number of cells expressing eGFP and eGFP intensity. Significantly higher 
transduction efficiency of IPLVs compared to IDLVs was observed only in eGFP intensity from CMVp-
eGFP vectors (Figures 2a, b). Representative images are shown in Figure 2c. We subsequently 
quantified specific cell types expressing eGFP in the transduced astroglial cultures, with a focus on 
astrocytes and neurons. Although there was no statistically significant difference in the number of 
total astrocytes (p = 0.14) or neurons (p = 0.15) between cultures (Figure S3), the percentage of 
eGFP-expressing cells from the various promoters used was significantly different (Figures 2d, e). 
eGFP was preferentially expressed in astrocytes (GFAP+) following LV-GFAPp vector transduction,  
whereas LV-SYNp vectors mediated eGFP expression in the majority of neurons (Tuj1+). Illustrative 
images are shown in Figures 2f, g.  
 
Hence, our in vitro data demonstrated that the cell-type specificity of eGFP expression was 
promoter-type dependent, with expression induced predominantly in neurons, in astrocytes, or in 
both neurons and astrocytes following transduction with LV-SYNp, LV-GFAPp or LV-CMVp vectors, 
respectively. The results from quantifying eGFP intensity moreover indicated higher transduction 
efficiency of IPLVs compared to IDLVs in most cases. 
 
In vivo neuronal specificity of LV-SYNp vectors 
 
In a bid to determine whether the neuronal specificity of LV-SYNp vectors was maintained in vivo, in 
particular in the PD animal model, IPLV- or IDLV-SYNp-eGFP vectors were injected into the right 
striatum of rats, followed by 6-OHDA lesioning two weeks later. Brains were harvested 5 months post 
vector injection. Successful transduction with widespread eGFP expression within the striatum was 
demonstrated (Figures 3a, b). No eGFP expression was detected in the non-injected striatal 
hemispheres (Figure 3c); however, there was anterograde presence of eGFP in the SNpr, from the 
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striatal injection site (Figure 3d). Quantification of levels of eGFP intensity showed no significant 
differences in transduction efficacy between IPLV- and IDLV-SYNp vectors (p = 0.12, Figure 3e). 
Further cell identification by morphology and marker expression confirmed that the majority of 
neurons were transduced; no significant astrocyte or microglia transduction was noticed (Figures 3f, 
g). These results are consistent with the in vitro findings, confirming the neuronal specificity of LV-
SYNp vectors. The data in particular demonstrated comparable transduction efficiency of IDLVs with 
their counterparts in the post-mitotic CNS environment.  
 
IGF-1 protective effects on rat primary cortical neuronal cultures 
 
Following the confirmation of LV transduction efficiency and cell-type specificity (through eGFP 
expression in vitro and in vivo), we investigated the neuroprotective effect of IGF-1 using trophic 
factor withdrawal on primary rat cortical neuronal cultures. Since neurons have been reported as 
the main source of brain IGF-134, IDLVs expressing Igf-1 were driven by SYNp or CMVp to enhance 
Igf-1 expression. IDLVs carrying either CMVp-eGFP, CMVp-Gdnf-IRES-eGFP, SFFVp-eGFP-CMVp-Igf-1, 
or SFFVp-eGFP-SYNp-Igf-1 were added to cell cultures 24 hours after cell plating. The culture medium 
was replaced with normal cortical neuronal medium (trophic factor-supported cultures) or with 
medium from which supplements had been withdrawn (trophic factor-free cultures), 3 days post 
vector transduction. Cell viability was determined by MTT assay 3 days afterwards and the results are 
shown in Figure 4a. Transduction efficiency was assessed by eGFP fluorescence (Figure 4b). Survival 
of cells in trophic factor-supported cultures was not significantly different between groups (p = 0.08). 
However, withdrawal of exogenous trophic factors led to the death of 20-30% of total cells in the 
non-transduced group (mock) or CMVp-eGFP-transduced group (negative control). Such reduction 
was significantly different (p < 0.001) when compared with IDLV-Igf-1 or -Gdnf groups. Indeed, 
transduction with IDLV-Gdnf vectors rescued more than 90% cells in trophic factor-free cultures 
although a significant difference (p = 0.02) in the survival of Gdnf-treated cells between trophic-
supported and trophic factor-free cultures was still observed. LV-Igf-1 vector transduction provided 
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complete protection, with similar cell survival regardless of trophic support in the cultures transduced 
with either CMVp-Igf-1 (p = 0.77) or SYNp-Igf-1 (p = 0.75) vectors. Moreover, IDLVs expressing Igf-1 
displayed similar transduction efficiency (p = 0.23) regardless of promoter type (CMVp or SYNp), 
Figures 4a-c. 
 
Using commercially available ELISA kits, we measured the level of IGF-1 (Figure 4c) and GDNF (Figure 
4d) produced in the transduced neuronal cultures. Transgenic production of IGF-1 was efficient and 
independent of trophic support and vector promoter (4.3 - 5.5 ng/ml at day 3, and 5.8 - 6.0 ng/ml at 
day 6). GDNF production was similarly efficient at 3 days post-transduction (~5.6 ng/ml), but seemed 
slightly reduced at day 6 (~4.7 ng/ml) and even lower in the absence of trophic support (~3.7 
ng/ml), matching the culture viability as shown by MTT assay (Figure 4a).  
 
Our results indicated efficient transgene expression from IDLVs in transduced primary neuronal 
cultures. A clear neuroprotective effect of IGF-1 on cultured neurons was observed, more potent 
than that observed with GDNF in parallel experiments, encouraging further testing of in vivo IGF-1 
neuroprotection.  
 
Lack of IGF-1 protective effects on dopaminergic neurons of 6-OHDA-lesioned rats 
 
We subsequently investigated LV-Igf-1 transduction in a 6-OHDA rat model of PD. IPLVs or IDLVs 
expressing Igf-1 were injected into the right striatum of rats, which then received a partial unilateral 
lesion with 6-OHDA two weeks after vector transduction. The amount of IGF-1 produced in the 
striatum was determined by ELISA 6 weeks post-vector administration (Figure 5a) showing no 
significant differences in the levels of IGF-1 in the contralateral hemispheres between groups (p = 
0.92). As expected, the levels in LV-Igf-1-injected hemispheres were significantly higher than in 
contralateral hemispheres and mock animals, regardless of vector integration proficiency or 
promoter type (p < 0.001). Differences in efficacy between vectors were noticed, with IPLVs being 
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more efficient than IDLVs, and SYNp promoter being particularly efficient in the IPLV configuration. 
IPLVs boosted IGF-1 levels 5 to 7-fold, while IDLVs provided about 2.5-fold increases (Figures 5a, b).  
 
We further examined the potential neuroprotective effects of IGF-1 on dopaminergic neurons by 
quantifying the total number of dopaminergic (TH+) cells remaining in the SNpc post 6-OHDA 
lesioning. Following intrastriatal injection of 6-OHDA, a depletion of 50-60% of dopaminergic cell 
bodies was detected in the ipsilateral hemispheres of mock-treated animals, as expected (Figure 
5c). The increased levels of IGF-1 did not appear to affect dopaminergic cell survival, as there was 
no significant difference in the number of TH+ cells remaining in the ipsilateral hemisphere between 
Igf-1-treated and mock-treated groups (p = 0.66, Figure 5c). Furthermore, the ratios of remaining TH+ 
cell number in the ipsilateral and contralateral hemispheres were not statistically different between 
groups (p = 0.69, Figure 5d). Illustrative images are shown in Figures 5e, f. 
 
The potential of IGF-1 exerting beneficial behavioral effects in PD rats was also examined. Figure 6a 
shows a weight chart and an experimental schedule of this behavioral experiment, in which 
amphetamine- or apomorphine-induced rotations were scored. Animals gained weight as 
expected, with a transient reduction following 6-OHDA lesioning and no statistical differences 
between groups. Net rotational asymmetry scores induced by amphetamine or apomorphine are 
summarized in Figures 6b, c, respectively. There was no statistical difference between groups in 
response to either amphetamine (p = 0.20) or apomorphine (p = 0.88). We further analyzed whether 
small differences might occur during the tests by comparing the number of rotations between 
groups at 10-min intervals. Neither amphetamine (Figures 6d-g) nor apomorphine (Figures 6h, i) 
mediated any significant difference. These in vivo results did not succeed in showing an effect of 
transgenic IGF-1 on dopaminergic neuron survival or behavioral recovery of 6-OHDA-lesioned rats, 
despite increased levels of IGF-1. 
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Discussion 
 
LVs can transduce both dividing and non-dividing CNS cells, with stable long-term expression of the 
transgene38. The development of IDLVs offers significantly reduced risk of insertional mutagenesis 
while maintaining similar transduction efficiency to the classical IPLVs in a range of cell types28, 29. We 
have already demonstrated neuroprotection mediated by IDLV-hGDNF in the 6-OHDA rodent 
model of PD30, supporting the feasibility of the use of IDLVs for Igf-1 delivery in the present study. Our 
work demonstrates that (1) LV-SYNp vectors provided efficient, long-lived and neuron-specific 
expression of transgene (through eGFP expression), with IDLVs as efficient as IPLVs; (2) Delivery of 
IDLV-Igf-1 vectors to primary cortical neuronal cells in vitro provided complete neuroprotection; (3) 
LV-mediated Igf-1 expression in 6-OHDA-lesioned rats, however, did not improve survival of 
dopaminergic cells or behavior of treated animals. 
 
For many years PD was considered a pure motor disorder with symptoms attributed to the loss of 
SNpc dopaminergic neurons and subsequent depletion of striatal dopamine. However, recent 
studies have indicated that the impairment affects other areas of the brain leading to a variety of 
non-motor symptoms39. One such symptom is cognitive dysfunction, occurring in one-third of PD 
patients40. Whilst the underlying pathology has not been elucidated, impaired pathways connecting 
the basal ganglia and the frontal cortex, which may subsequently cause a degeneration of cortical 
neurons, have been suggested to contribute to this decline39. IGF-1, with its mitogenic properties 
exerted through the PI3K/Akt pathway, improved survival of rat cortical neurons41, 42. Our in vitro data 
confirm the protective effects of IGF-1 on these neurons, although we obtained effective protection 
at much lower levels of IGF-1 and by transduction with IDLVs rather than direct administration of IGF-
1 protein. 
 
In normal CNS tissue, IGF-1 is secreted by neurons34, unlike other neurotrophic factors produced by 
glia, and acts upon nearby IGF-1 receptors in an autocrine manner. The use of neuronal-specific 
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promoters, such as SYNp, to drive Igf-1 expression is therefore rational31. Indeed, SYNp has been 
extensively used to target expression of transgenes to neurons in vitro and in vivo31, 43. As shown, IPLV- 
and IDLV-SYNp-eGFP vectors transduced predominantly neurons in both primary cell cultures and 
PD rat striata. Importantly, the in vivo data, consistent with other studies43, 44, demonstrated that 
striatal administration of vectors driven by SYNp led to eGFP detection in the SN, possibly due to 
anterograde axonal trafficking. At present, it is unclear whether the vectors or transgene-induced 
proteins are transported. However, an involvement of endocytosis likely explains the trans-synaptic 
transfer from neuron to neuron45. This appears as an advantage in PD therapy since a transgene can 
be administered into the striatum but provide therapeutic effects to both the striatum and the SN. 
Technically, intrastriatal injection of vectors is simpler and safer than intranigral injection46 although a 
possible higher dose (volume) of vectors is required for intrastriatal injection.  
 
The most likely explanation for the failure of transgenic Igf-1 to mediate in vivo neuroprotection in our 
study is the insufficient levels of IGF-1 achieved. IGF-1 was previously used at 30-150 ng/ml in 
embryonic mesencephalic neuronal cultures8, 47, while we obtained ~5 ng/ml IGF-1 by transgenic 
expression in vitro, but still achieved complete neuroprotection. However, in vivo neuroprotection in 
6-OHDA-lesioned rats has been shown with continuous intracerebroventricular IGF-1 infusion for a 
week at 100 µg/ml (10 µg in total)21, which is many orders of magnitude higher than the 15-35 pg/mg 
IGF-1 obtained in the current study. Ebert et al.48 have previously reported the protective effects of 
IGF-1 on 6-OHDA-lesioned rats, which were achieved following striatal transplantation of neural 
progenitor cells expressing LV-IGF-1. The authors did not show at which levels IGF-1 provided such 
protection, and it could not be ruled out that other factors provided by the progenitor cells were 
involved. Indeed, in some systems progenitor cells can improve both cell survival and animal 
behavior in PD models against both 6-OHDA and MPTP toxicity49, 50. It is also noteworthy that to 
obtain similar protection on dopaminergic cell survival, previous investigators have used purified IGF-
1 at concentrations about 30 times higher than that of GDNF8, 51. This is probably necessary due to 
the half-life of IGF-1 being less than 10 min whereas GDNF can last for 6-8 days52, 53. Since the doses 
19 
 
of Igf-1 expressing vectors used in this study are similar to those used previously for delivery of other 
neurotrophic factor (i.e., GDNF) with demonstrated therapeutic benefits30, insufficient in vivo 
expression of Igf-1 as presented here is an obvious challenge for the application of IGF-1 gene 
therapy in PD. A vector dosing study should be carried out to determine the doses of Igf-1-expressing 
vectors that can mediate neuroprotection. The use of more concentrated vector stocks, stronger 
transcription regulation sequences, codon-optimization of the transgene and stabilization of the 
transgenic IGF-1 protein should be explored to develop an Igf-1 vector of demonstrated pre-clinical 
efficacy. 
 
In summary, our studies provide evidence for efficient transgenic delivery by IDLVs in PD and support 
their use in the CNS as a safer delivery system. Our data, moreover, confirm neuroprotection by IGF-1 
on cultured cortical neurons, resulting from efficient IDLV-Igf-1 delivery. However, IGF-1-mediated 
protection through transgenic Igf-1 expression was unsuccessful in 6-OHDA-lesioned rats. Further 
studies are required to develop an effective Igf-1 delivery system and to ascertain the benefit of IGF-
1 gene therapy for PD treatment. 
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Figure legends 
 
Figure 1: LV-mediated eGFP expression in VM neuronal cultures. Rat primary VM neuronal 
cultures were transduced with IPLV- or IDLV-eGFP vectors at MOI 10 (eGFP transducing units), one 
day after cell seeding. (a) The percentage of total cells expressing eGFP and (b) intensity of 
eGFP fluorescence were evaluated 3 days post-vector transduction. (c) Representative images 
are shown; scale bars = 50 µm; nuclei were stained blue with DAPI. In cultures transduced with 
IPLVs, (d) the total TH+ cell number per well and (e) percentage of TH+ cells expressing eGFP were 
additionally quantified. Total TH+ cell number was not significantly different between groups; 
however, efficient eGFP expression by CMVp and SYNp, and not GFAPp, was observed. (f) 
Representative images illustrate fluorescence co-localization of TH+ and eGFP+ cells. Nuclei were 
stained blue with DAPI; TH+ cells were stained red; arrows indicate TH+/eGFP+ cells; scale bars = 20 
µm. Statistical analysis was by two-way ANOVA (in a, b) or one-way ANOVA (in d, e) followed by 
Bonferroni’s post-hoc test. Error bars represent the S.E.M; n = 3; *p<0.05, **p<0.01, ***p<0.001.  
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Figure 2: LV-mediated eGFP expression in VM astroglial cultures. Cell cultures were transduced 
with IPLVs (n = 3) or IDLVs (n = 3) at MOI 10 (eGFP transducing units) 3 days after plating the cells. 
(a) Percentage of cells expressing eGFP and (b) intensity of eGFP fluorescence were evaluated 3 
days post transduction. Significant differences were observed in cell-type specificity between 
SYNp and other promoters whereas the difference between IPLVs and IDLVs was only significant 
in eGFP intensity expressed from CMVp-eGFP vectors. (c) Representative images are shown; 
scale bars = 50 µm; nuclei were stained blue with DAPI. (d) Astrocytes or (e) neurons expressing 
eGFP were quantified as percentages of total astrocytes or neurons, as appropriate, showing 
significantly different cell-type specificity of the vectors, with LV-GFAPp predominantly targeting 
astrocytes and LV-SYNp predominantly targeting neurons. (f, g) Representative images from 
cultures transduced with IPLVs (as an example) illustrating the types of cells transduced. (f) 
Astrocytes were identified by GFAP+ staining, whereas (g) neurons were identified through Tuj1+ 
staining. Nuclei were stained blue with DAPI; GFAP+ or Tuj1+ cells were stained red; scale bars are 
50 µm. Data were analyzed by one- or two-way ANOVA followed by Bonferroni’s post-hoc test. 
Error bars represent the S.E.M; *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3. Neuronal specificity of LV-SYNp vectors in 6-OHDA-treated rat striata. The right striata 
were injected with IPLV- or IDLV-SYNp-eGFP vectors 2 weeks before unilateral 6-OHDA lesioning 
at the same positions as for vector administration. Animal brains were harvested 5 months later. 
Representative serial striatal sections from (a) IPLV- and (b) IDLV-eGFP-injected animals show 
both vector injection site and area of vector spread. (c) No eGFP expression in the non-injected 
left striatal hemisphere but (d) anterograde eGFP presence in the corresponding SNpr (co-
stained in red for TH+ cells) was detected. (e) An evaluation of eGFP levels indicated no 
significant difference in vector transduction efficiency between IPLVs and IDLVs. (f, g) 
Representative high-magnification images from IPLV- and IDLV-eGFP-injected striata, 
respectively, are shown. Cell-type identification by morphology and marker expression 
demonstrated the majority of eGFP+ cells were neurons (NeuN+); no significant astrocyte (GFAP+) 
or microglia (Iba1+) transduction was observed. Nuclei were stained blue with DAPI; scale bar: (a-
c) 2000 µm; (d) 500 µm; (f, g) 100 µm (insets, 20 µm). Data in (e) were analyzed for statistical 
significance by two-tailed Student’s t-test; error bars represent the S.E.M.; n = 3 per group.  
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Figure 4. IGF-1 protection on rat primary embryonic cortical neurons. Rat primary cortical 
neuronal cultures were transduced with IDLVs expressing Igf-1, Gdnf (positive control), or eGFP 
(negative control) one day after cell plating. Trophic factor withdrawal was applied 3 days post-
transduction and cells were cultured for an additional 3 days. (a) Results from an MTT assay 
indicated cell survival in trophic-supported cultures was not significantly different between 
groups, whereas in trophic-free cultures, IDLV-Igf-1 or IDLV-Gdnf displayed enhanced survival. 
Data are shown as percentages compared to the mock (non-transduced group) in trophic-
support cultures. Statistical analysis by one-way ANOVA and Dunnett’s post-hoc test; error bars 
represent the S.E.M; n = 3. (b) Representative images illustrate efficient transduction of the 
cortical cell cultures through eGFP expression; scale bar = 50 μm. (c, d) ELISA results presenting 
levels of (c) IGF-1 and (d) GDNF produced in transduced cortical neuronal cultures at days 3 and 
6 following IDLV transduction. Samples were run in duplicate with n = 2. Black bars: trophic-
support groups, white bars: trophic-free groups. 
 
5 
 
Figure 5: Igf-1 expression in rat striata does not mediate protective effects on SNpc dopaminergic 
neurons. CMVp-Igf-1 and SYNp-Igf-1 vectors, either IPLVs or IDLVs, were injected into the right 
striatum of rats 2 weeks prior to 6-OHDA lesioning; mock-treated animals received 0.9% saline. (a) 
Quantification of IGF-1 production showing no significant difference in contralateral hemispheres 
between groups; in contrast, significant vector-mediated IGF-1 production was observed in the 
ipsilateral hemispheres. (b) Ratios of IGF-1 levels between ipsilateral and contralateral 
hemispheres. Data were statistically analyzed by one-way ANOVA followed by Bonferroni’s post-
hoc test; error bars represent the S.E.M; n = 5 per group. (c) Total TH+ cell numbers (per brain 
section) in the SNpc were counted 6 weeks after vector transduction. (d) Ratio of remaining 
SNpc TH+ cells between ipsilateral and contralateral hemispheres. The lesion caused a reduction 
to about 40-50% in all groups, with no significant difference in TH+ cell survival observed between 
Igf-1-treated groups and mock. Statistical analysis by one-way ANOVA and Bonferroni’s post-hoc 
test; error bars represent the S.E.M; n = 5 per group. (e, f) Representative images of SN sections 
demonstrate the depletion of TH+ cells in the ipsilateral hemisphere (right) compared to the 
contralateral hemisphere (left), with no difference between (e) mock and (f) Igf-1-treated 
groups; scale bar = 500 μm. 
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Figure 6: Drug-induced rotational tests. (a) Experimental design and weight of animals are shown. 
Animals had normal weight gain, with no statistical difference between groups, except for a 
reduction on the week after 6-OHDA lesioning. (b, c) Summaries of net rotational asymmetry 
induced by (b) amphetamine or (c) apomorphine. Following 30 min acclimation (baseline), rats 
were injected with the corresponding drug. Net 360o rotations were scored for 90 min. For 
amphetamine, ipsilateral turns were given positive values and contralateral turns were counted 
as negative values; for apomorphine, contralateral turns were scored as positive and ipsilateral 
as negative. No significant behavioral changes between animal groups were detected in either 
test. (d-i) The number of rotations per 10 minute interval was scored. (d-g) Amphetamine-
induced rotational tests at weeks 4, 5, 6, 7, respectively; (h, i) apomorphine-induced rotational 
tests at weeks 4 and 7. No significant difference between groups was observed. Statistical 
analysis by two-way ANOVA and Bonferroni's post-hoc test; error bars represent the S.E.M; n = 5 
per group. 
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Supplementary materials 
 
Figure S1: Optimization of LV transduction. E14 rat primary ventral mesencephalic (VM) neuronal 
cultures were transduced with IPLV-CMVp-eGFP vectors at MOI 1, 3, 10 or 30 (eGFP transducing 
units/ml) one day after cell seeding. (a) The number of eGFP+ cells, (b) the number of total cells 
(DAPI+) and (c) the intensity of eGFP fluorescence were evaluated 3 days post-transduction. 
Cultures transduced at MOI 10 displayed the best results regarding the combined number of eGFP+ 
cells and eGFP intensity. Statistical analysis by one-way ANOVA and Bonferroni’s post-hoc test; error 
bars represent the S.E.M; n = 3; *p<0.05, **p<0.01. (d) Representative images are shown; scale bars = 
50 µm; nuclei were stained blue with DAPI. 
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Figure S2: Composition of rat primary VM cell cultures. E14 rat VM cells were cultured under specific 
conditions for the growth of either neurons or glia. Cell cultures were characterised by 
immunocytochemistry at day 4 in vitro for (a) neuronal cultures (n = 3) and day 6 in vitro for (b) 
astroglial cultures (n = 2). Representative images demonstrating the composition of (c) neuronal and 
(d) glial cultures are shown. Scale bars = 50 µm. Nuclei were stained blue with DAPI. Red cells were 
positive with primary antibodies against the protein markers indicated on images: neurons are NeuN+ 
or Tuj1+; astrocytes are GFAP+; microglia are Iba1+; GABAergic neurons are GAD67+; glutamatergic 
neurons are VGLUT1+; and dopaminergic neurons are TH+ cells. Uncharacterized cells were negative 
with all tested antibodies. 
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Figure S3: Quantification of astrocytes and neurons in rat VM astroglial cultures transduced with LVs. 
Primary rat VM astroglial cultures were transduced with IPLV-eGFP (n = 3) at MOI 10 (eGFP 
transducing units), 3 days after cell seeding. Total numbers of (a) astrocytes (GFAP+) and (b) 
neurons (Tuj1+) were evaluated 3 days post-vector transduction demonstrating no significant 
difference in cell number between groups. Data were statistically analysed by one-way ANOVA 
and Bonferroni’s post-hoc test. Error bars represent the S.E.M. 
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